Liver mass diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 5: Line 5:
==Overview==
==Overview==


Liver biopsy is the gold standard test for the diagnosis of liver mass. Common indications for biopsy in liver mass include suspected hepatocellular carcinoma, and unspecific imaging findings. The most important contraindication for biopsy in liver mass is suspected liver hemangioma.<ref name="libre">Hepatocellular carcinoma. Libre Pathology.https://librepathology.org/wiki/Hepatocellular_carcinoma Accessed on March 28, 2016 </ref><ref name="pmid8201212">{{cite journal |vauthors=Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, Servida E |title=The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis |journal=J. Hepatol. |volume=20 |issue=1 |pages=117–21 |year=1994 |pmid=8201212 |doi= |url=}}</ref>
Liver biopsy is the gold standard test for the diagnosis of liver mass. Common indications for biopsy in liver mass include suspected [[hepatocellular carcinoma]], and unspecific imaging findings. The most important contraindication for biopsy in liver mass is suspected liver [[hemangioma]].<ref name="libre">Hepatocellular carcinoma. Libre Pathology.https://librepathology.org/wiki/Hepatocellular_carcinoma Accessed on March 28, 2016 </ref><ref name="pmid8201212">{{cite journal |vauthors=Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, Servida E |title=The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis |journal=J. Hepatol. |volume=20 |issue=1 |pages=117–21 |year=1994 |pmid=8201212 |doi= |url=}}</ref>


==Biopsy==
==Biopsy==
Line 41: Line 41:
=== Contraindications ===
=== Contraindications ===
*Contraindications for biopsy in liver mass, include:<ref name="pmid8201212">{{cite journal |vauthors=Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, Servida E |title=The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis |journal=J. Hepatol. |volume=20 |issue=1 |pages=117–21 |year=1994 |pmid=8201212 |doi= |url=}}</ref>
*Contraindications for biopsy in liver mass, include:<ref name="pmid8201212">{{cite journal |vauthors=Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, Servida E |title=The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis |journal=J. Hepatol. |volume=20 |issue=1 |pages=117–21 |year=1994 |pmid=8201212 |doi= |url=}}</ref>
**Suspected hemangioma
**Suspected [[hemangioma]]
**Adenomas
**Adenomas
**Patients on of anticoagulant therapy
**Patients on of [[anticoagulant]] therapy
**Unstable medical conditions (eg. acute heart failure)
**Unstable medical conditions (e.g. [[Congestive heart failure|acute heart failure]])


=== Complications ===
=== Complications ===

Revision as of 21:06, 15 February 2018

Liver Mass Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differential Diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Evaluation of Liver Mass

Staging

History and Symptoms

Physical Examination

Laboratory Studies

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Liver mass diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Liver mass diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Liver mass diagnostic study of choice

CDC on Liver mass diagnostic study of choice

Liver mass diagnostic study of choice in the news

Blogs on Liver mass diagnostic study of choice

Directions to Hospitals Treating bone or soft tissue mass

Risk calculators and risk factors for Liver mass diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

Liver biopsy is the gold standard test for the diagnosis of liver mass. Common indications for biopsy in liver mass include suspected hepatocellular carcinoma, and unspecific imaging findings. The most important contraindication for biopsy in liver mass is suspected liver hemangioma.[1][2]

Biopsy

Biopsy is always indicated in patients presenting with liver mass to rule out malignancy. Biopsy findings associated with liver mass will depend on tumor histology. [2]

Indications

Indications for biopsy in liver mass, include:
  • Suspected hepatocellular carcinoma[2]
  • Unspecific and inconclusive liver mass imaging findings

Types

  • Per-cutaneous, ultrasound-guided liver biopsy
  • Laparoscopic liver biopsy
  • Transjugular liver biopsy
DIsease Findings on Biopsy
Focal nodular hyperplasia Ductular reaction with varied intensity at the junction of the fibrous septa with the hepatocellular component, 
Hepato-cellular carcinoma Two out of the following three positive stains upon liver biopsy confirm HCC:[3][4]
Cirrhosis
  • Bridging fibrous septa

Contraindications

Complications

Complications for for biopsy in liver mass, include:[2]

  • Bleeding
  • Seeding of neoplastic cell

References

  1. Hepatocellular carcinoma. Libre Pathology.https://librepathology.org/wiki/Hepatocellular_carcinoma Accessed on March 28, 2016
  2. 2.0 2.1 2.2 2.3 2.4 Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, Servida E (1994). "The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis". J. Hepatol. 20 (1): 117–21. PMID 8201212.
  3. "Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia". Hepatology. 49 (2): 658–64. 2009. doi:10.1002/hep.22709. PMID 19177576.
  4. Karabork A, Kaygusuz G, Ekinci C (2010). "The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma". Pathol. Res. Pract. 206 (8): 572–7. doi:10.1016/j.prp.2010.03.004. PMID 20400233.